IRIS Accounts Production v25.2.0.378 02582192 director 1.4.24 31.3.25 31.3.25 Medium entities true false true true false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. 'A' Ordinary 1.00000 'C' Ordinary 1.00000 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh025821922024-03-31025821922025-03-31025821922024-04-012025-03-31025821922023-03-31025821922023-04-012024-03-31025821922024-03-3102582192ns15:EnglandWales2024-04-012025-03-3102582192ns14:PoundSterling2024-04-012025-03-3102582192ns10:Director12024-04-012025-03-3102582192ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3102582192ns10:MediumEntities2024-04-012025-03-3102582192ns10:Audited2024-04-012025-03-3102582192ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-04-012025-03-3102582192ns10:Medium-sizedCompaniesRegimeForAccounts2024-04-012025-03-3102582192ns10:FullAccounts2024-04-012025-03-3102582192ns10:OrdinaryShareClass12024-04-012025-03-3102582192ns10:OrdinaryShareClass32024-04-012025-03-310258219221ns10:OrdinaryShareClass12024-04-012025-03-3102582192ns10:RegisteredOffice2024-04-012025-03-3102582192ns5:CurrentFinancialInstruments2025-03-3102582192ns5:CurrentFinancialInstruments2024-03-3102582192ns5:ShareCapital2025-03-3102582192ns5:ShareCapital2024-03-3102582192ns5:CapitalRedemptionReserve2025-03-3102582192ns5:CapitalRedemptionReserve2024-03-3102582192ns5:RetainedEarningsAccumulatedLosses2025-03-3102582192ns5:RetainedEarningsAccumulatedLosses2024-03-3102582192ns5:ShareCapital2023-03-3102582192ns5:RetainedEarningsAccumulatedLosses2023-03-3102582192ns5:CapitalRedemptionReserve2023-03-3102582192ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3102582192ns5:CapitalRedemptionReserve2023-04-012024-03-3102582192ns5:RetainedEarningsAccumulatedLosses2024-04-012025-03-3102582192ns5:CapitalRedemptionReserve2024-04-012025-03-3102582192ns5:LeaseholdImprovements2024-04-012025-03-3102582192ns5:PlantMachinery2024-04-012025-03-3102582192ns5:FurnitureFittings2024-04-012025-03-3102582192ns15:UnitedKingdom2024-04-012025-03-3102582192ns15:UnitedKingdom2023-04-012024-03-3102582192ns15:Europe2024-04-012025-03-3102582192ns15:Europe2023-04-012024-03-3102582192ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2024-04-012025-03-3102582192ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-04-012024-03-3102582192ns5:OwnedAssets2024-04-012025-03-3102582192ns5:OwnedAssets2023-04-012024-03-310258219212024-04-012025-03-310258219212023-04-012024-03-3102582192ns10:OrdinaryShareClass32023-04-012024-03-3102582192ns5:LeaseholdImprovements2024-03-3102582192ns5:PlantMachinery2024-03-3102582192ns5:FurnitureFittings2024-03-3102582192ns5:LeaseholdImprovements2025-03-3102582192ns5:PlantMachinery2025-03-3102582192ns5:FurnitureFittings2025-03-3102582192ns5:LeaseholdImprovements2024-03-3102582192ns5:PlantMachinery2024-03-3102582192ns5:FurnitureFittings2024-03-3102582192ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3102582192ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3102582192ns5:WithinOneYear2025-03-3102582192ns5:WithinOneYear2024-03-3102582192ns5:BetweenOneFiveYears2025-03-3102582192ns5:BetweenOneFiveYears2024-03-3102582192ns5:AllPeriods2025-03-3102582192ns5:AllPeriods2024-03-3102582192ns5:DeferredTaxation2024-03-3102582192ns5:DeferredTaxation2025-03-3102582192ns10:OrdinaryShareClass12025-03-3102582192ns10:OrdinaryShareClass32025-03-3102582192ns5:RetainedEarningsAccumulatedLosses2024-03-3102582192ns5:CapitalRedemptionReserve2024-03-3102582192ns5:OtherRelatedParties2024-04-012025-03-3102582192ns5:OtherRelatedParties2023-04-012024-03-31
REGISTERED NUMBER: 02582192 (England and Wales)













Strategic Report, Report of the Director and

Financial Statements

for the Year Ended 31 March 2025

for

V.H. Bio Limited

V.H. Bio Limited (Registered number: 02582192)






Contents of the Financial Statements
for the Year Ended 31 March 2025




Page

Company Information 1

Strategic Report 2

Report of the Director 3

Report of the Independent Auditors 4

Income Statement 7

Other Comprehensive Income 8

Balance Sheet 9

Statement of Changes in Equity 10

Cash Flow Statement 11

Notes to the Cash Flow Statement 12

Notes to the Financial Statements 13


V.H. Bio Limited

Company Information
for the Year Ended 31 March 2025







DIRECTOR: A J Wortley



REGISTERED OFFICE: Unit 11B
Station Approach
Team Valley Trading Estate
Gateshead
Tyne and Wear
NE11 0ZF



REGISTERED NUMBER: 02582192 (England and Wales)



SENIOR STATUTORY AUDITOR: Gary Ellis BA BFP FCA



AUDITORS: Clive Owen LLP
Chartered Accountants and Statutory Auditors
Kepier House
Belmont Business Park
Durham
DH1 1TW

V.H. Bio Limited (Registered number: 02582192)

Strategic Report
for the Year Ended 31 March 2025

The director presents her strategic report for the year ended 31 March 2025.

Review of Business

The business exceeded expectations for the financial year finishing 18.6% higher than forecast and 8.4% growth on turnover compared to the previous year (2025 : £12.2m; 2024 : £11.2m).

Most of the growth came from the major product group which accounts for 88% of the total product sales with a 10% year on year growth; the growth came from new product sales and new customers.

There was some decline in other product groups; due to changing markets, changes to global guidelines, strong competition.

The company was successful on all the objectives, obtaining and maintaining all the regulatory accreditations it requires to operate. Maintained the majority market share with exceptional customer service and keeping a strong focus on support and education.

Principal Risks and Uncertainties

The contracts for distribution with our supply partners is key to the business, maintaining these relationships and meeting their obligations and expectations in-line with our own objectives.

Competition is a significant risk to the business, maintaining the market share is key, whilst trying to develop new markets.

We believe we can mitigate these risks and uncertainties by maintaining customer and partner relationships, providing exceptional support, knowledge and education.

ON BEHALF OF THE BOARD:





A J Wortley - Director


27 August 2025

V.H. Bio Limited (Registered number: 02582192)

Report of the Director
for the Year Ended 31 March 2025

The director presents her report with the financial statements of the company for the year ended 31 March 2025.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of importation and distribution of laboratory equipment and consumables.

DIVIDENDS
The total distribution of dividends for the year ended 31 March 2025 will be £186,800 (2024: £136,800).

DIRECTOR
A J Wortley held office during the whole of the period from 1 April 2024 to the date of this report.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Strategic Report, the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable her to ensure that the financial statements comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and she has taken all the steps that she ought to have taken as a director in order to make herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Clive Owen LLP, are deemed to be re-appointed under section 487(2) of the Companies Act 2006.

ON BEHALF OF THE BOARD:





A J Wortley - Director


27 August 2025

Report of the Independent Auditors to the Members of
V.H. Bio Limited

Opinion
We have audited the financial statements of V.H. Bio Limited (the 'company') for the year ended 31 March 2025 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information
The director is responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Director, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Director for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Director have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
V.H. Bio Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Director.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of director's remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of director
As explained more fully in the Statement of Director's Responsibilities set out on page three, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
V.H. Bio Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.
Our audit must be alert to the risk of manipulation of the financial statements and seek to understand the incentives and opportunities for management to achieve this.

We undertook the following procedures to identify and respond to these risks of non-compliance:
- Understanding the key legal and regulatory frameworks that are applicable to the Company. We communicated identified laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit. We determined the most significant of these to be financial reporting legislation, taxation legislation, health & safety, product quality and employment law.
- Enquiry of directors and management as to policies and procedures to ensure compliance and any known instances of non-compliance.
- Review of board minutes and correspondence with regulators.
- Enquiry of directors and management as to areas of the financial statements susceptible to fraud and how these risks are managed.
- Challenging management on key estimates, assumptions and judgements made in the preparation of the financial statements. The key areas of uncertainty are disclosed in the accounting policies.
- Identifying and testing unusual journal entries, with a particular focus on manual journal entries.

Through these procedures, we did not become aware of actual or suspected non-compliance.
We planned and performed our audit in accordance with auditing standards but owing to the inherent limitations of procedures required in these areas, there is an unavoidable risk that we may not have detected a material misstatement in the accounts. The further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve concealment, collusion, forgery, misrepresentations, or override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Gary Ellis BA BFP FCA (Senior Statutory Auditor)
for and on behalf of Clive Owen LLP
Chartered Accountants and Statutory Auditors
Kepier House
Belmont Business Park
Durham
DH1 1TW

28 August 2025

V.H. Bio Limited (Registered number: 02582192)

Income Statement
for the Year Ended 31 March 2025

2025 2024
as restated
Notes £    £   

TURNOVER 3 12,218,309 11,272,876

Cost of sales (9,392,245 ) (8,750,085 )
GROSS PROFIT 2,826,064 2,522,791

Administrative expenses (1,244,124 ) (1,280,747 )
1,581,940 1,242,044

Other operating income 78,770 65,913
OPERATING PROFIT 5 1,660,710 1,307,957

Interest receivable and similar income 261,605 202,345
1,922,315 1,510,302

Interest payable and similar expenses 6 (193,762 ) 29,324
PROFIT BEFORE TAXATION 1,728,553 1,539,626

Tax on profit 7 (435,288 ) (387,255 )
PROFIT FOR THE FINANCIAL YEAR 1,293,265 1,152,371

V.H. Bio Limited (Registered number: 02582192)

Other Comprehensive Income
for the Year Ended 31 March 2025

2025 2024
as restated
Notes £    £   

PROFIT FOR THE YEAR 1,293,265 1,152,371


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

1,293,265

1,152,371

V.H. Bio Limited (Registered number: 02582192)

Balance Sheet
31 March 2025

2025 2024
as restated
Notes £    £   
FIXED ASSETS
Tangible assets 10 143,273 49,823

CURRENT ASSETS
Stocks 11 972,450 730,429
Debtors 12 1,756,449 2,105,061
Cash at bank and in hand 8,388,587 6,925,184
11,117,486 9,760,674
CREDITORS
Amounts falling due within one year 13 (2,911,784 ) (2,589,569 )
NET CURRENT ASSETS 8,205,702 7,171,105
TOTAL ASSETS LESS CURRENT
LIABILITIES

8,348,975

7,220,928

PROVISIONS FOR LIABILITIES 16 (34,038 ) (12,456 )
NET ASSETS 8,314,937 7,208,472

CAPITAL AND RESERVES
Called up share capital 17 90 60
Capital redemption reserve 18 10,870 10,870
Retained earnings 18 8,303,977 7,197,542
SHAREHOLDERS' FUNDS 8,314,937 7,208,472

The financial statements were approved by the director and authorised for issue on 27 August 2025 and were signed by:





A J Wortley - Director


V.H. Bio Limited (Registered number: 02582192)

Statement of Changes in Equity
for the Year Ended 31 March 2025

Called up Capital
share Retained redemption Total
capital earnings reserve equity
£    £    £    £   
Balance at 1 April 2023 60 6,181,971 10,870 6,192,901

Changes in equity
Total comprehensive income - 1,152,371 - 1,152,371
Dividends - (136,800 ) - (136,800 )
Balance at 31 March 2024 60 7,197,542 10,870 7,208,472

Changes in equity
Total comprehensive income - 1,293,265 - 1,293,265
Dividends - (186,800 ) - (186,800 )
Bonus share issue 30 (30 ) - -
Balance at 31 March 2025 90 8,303,977 10,870 8,314,937

V.H. Bio Limited (Registered number: 02582192)

Cash Flow Statement
for the Year Ended 31 March 2025

2025 2024
as restated
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 2,210,139 1,062,242
Tax paid (509,321 ) (169,154 )
Net cash from operating activities 1,700,818 893,088

Cash flows from investing activities
Purchase of tangible fixed assets (118,458 ) (5,469 )
Sale of tangible fixed assets - 15,743
Profit/(loss) on forward contracts (193,762 ) 29,324
Interest received 261,605 197,853
Net cash from investing activities (50,615 ) 237,451

Cash flows from financing activities
Equity dividends paid (186,800 ) (136,800 )
Net cash from financing activities (186,800 ) (136,800 )

Increase in cash and cash equivalents 1,463,403 993,739
Cash and cash equivalents at beginning of
year

2

6,925,184

5,931,445

Cash and cash equivalents at end of year 2 8,388,587 6,925,184

V.H. Bio Limited (Registered number: 02582192)

Notes to the Cash Flow Statement
for the Year Ended 31 March 2025

1. RECONCILIATION OF PROFIT FOR THE FINANCIAL YEAR TO CASH GENERATED FROM
OPERATIONS

2025 2024
as restated
£    £   
Profit for the financial year 1,293,265 1,152,371
Depreciation charges 25,008 26,101
Profit on disposal of fixed assets - (1,473 )
Loss on revaluation of fixed assets - 10,373
Finance costs 193,762 (29,324 )
Finance income (261,605 ) (202,345 )
Taxation 435,288 387,255
1,685,718 1,342,958
Increase in stocks (242,021 ) (135,677 )
Decrease/(increase) in trade and other debtors 348,612 (787,110 )
Increase in trade and other creditors 417,830 642,071
Cash generated from operations 2,210,139 1,062,242

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 March 2025
31.3.25 1.4.24
£    £   
Cash and cash equivalents 8,388,587 6,925,184
Year ended 31 March 2024
31.3.24 1.4.23
as restated
£    £   
Cash and cash equivalents 6,925,184 5,931,445


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.4.24 Cash flow At 31.3.25
£    £    £   
Net cash
Cash at bank and in hand 6,925,184 1,463,403 8,388,587
6,925,184 1,463,403 8,388,587
Total 6,925,184 1,463,403 8,388,587

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

V.H. Bio Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

There were no material departures from that standard.

The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.

Significant judgements and estimates
In the application of the company's accounting policies, management are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from the estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised when the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Significant judgements in applying the company's accounting policies
In preparing these financial statements management do not consider there were any significant area of judgement that were required in applying the company's accounting policies as set out in this note.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Income recognition
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. This is usually at the point that the goods have been dispatched.

Turnover from service contracts is recognised across the life of the contract.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - over period of the lease
Plant and machinery - 50% on cost and 20% on cost
Fixtures and fittings - 50% on cost

Tangible fixed assets are measured at cost less accumulated depreciation and impairment losses.

Stocks
Stocks are valued at the lower of cost and estimated selling price less costs to sell, after making due allowance for obsolete and slow moving items.

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

2. ACCOUNTING POLICIES - continued

Financial instruments
Basic financial instruments are recognised at amortised cost. Derivative financial instruments, such as forward foreign currency contracts, are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Operating leasing commitments
Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

Dividends
Dividends and other distributions to the company's shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the shareholders. These amounts are recognised in the statement of changes in equity.

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

3. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2025 2024
as restated
£    £   
United Kingdom 11,300,821 10,342,224
Europe 917,488 930,652
12,218,309 11,272,876

4. EMPLOYEES AND DIRECTORS
2025 2024
as restated
£    £   
Wages and salaries 567,747 615,685
Social security costs 59,024 64,873
Other pension costs 168,336 181,218
795,107 861,776

The average number of employees during the year was as follows:
2025 2024
as restated

Directors 1 1
Staff 11 12
12 13

2025 2024
as restated
£    £   
Director's remuneration 9,894 9,100
Director's pension contributions to money purchase schemes 60,000 60,000

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 1 1

The director is considered to be key management personnel.

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

5. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

2025 2024
as restated
£    £   
Other operating leases 358 -
Depreciation - owned assets 25,008 26,101
Profit on disposal of fixed assets - (1,473 )
Auditors' remuneration 12,450 10,250

6. INTEREST PAYABLE AND SIMILAR EXPENSES
2025 2024
as restated
£    £   
Unrealised (profit)/loss on
foreign exchange forward
contracts 193,762 (29,324 )
193,762 (29,324 )

7. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2025 2024
as restated
£    £   
Current tax:
UK corporation tax 413,706 398,212

Deferred tax 21,582 (10,957 )
Tax on profit 435,288 387,255

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2025 2024
as restated
£    £   
Profit before tax 1,728,553 1,539,626
Profit multiplied by the standard rate of corporation tax in the UK of 25%
(2024 - 25%)

432,138

384,907

Effects of:
Expenses not deductible for tax purposes 3,150 2,348



Total tax charge 435,288 387,255

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

8. DIVIDENDS
2025 2024
as restated
£    £   
'C' Ordinary shares of £1 each
Interim 186,800 136,800

9. PRIOR YEAR ADJUSTMENT

In accordance with FRS 102, the Company has reviewed the presentation of its expenses and determined that certain costs previously included within administrative expenses are more appropriately classified as cost of sales. This reclassification better reflects the nature of these costs and provides more relevant and reliable information to users of the financial statements.

As a result, the comparative figures for the year ended 31 March 2024 have been restated as follows:

Income Statement (extract)As previously reportedReclassificationAs restated
Turnover11,272,876-11,272,876
Cost of Sales(8,689,310)(60,775)(8,750,085)
Gross Profit2,583,566(60,775)2,522,791
Administrative Expenses(1,341,522)60,775(1,280,747)
Other Operating Income65,913-65,913
Operating Profit1,307,957-1,307,957


This reclassification has no impact on the previously reported profit before tax, total comprehensive income, or net assets.

10. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings Totals
£    £    £    £   
COST
At 1 April 2024 30,080 238,956 17,565 286,601
Additions 24,438 94,020 - 118,458
Disposals - (1,532 ) - (1,532 )
At 31 March 2025 54,518 331,444 17,565 403,527
DEPRECIATION
At 1 April 2024 30,080 189,133 17,565 236,778
Charge for year 4,445 20,563 - 25,008
Eliminated on disposal - (1,532 ) - (1,532 )
At 31 March 2025 34,525 208,164 17,565 260,254
NET BOOK VALUE
At 31 March 2025 19,993 123,280 - 143,273
At 31 March 2024 - 49,823 - 49,823

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

11. STOCKS
2025 2024
as restated
£    £   
Stocks 972,450 730,429

There is no significant difference between the replacement cost of the stocks and its carrying amount.

Stocks are stated after provisions for impairment of £nil (2024: £nil).

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
as restated
£    £   
Trade debtors 1,585,182 1,944,601
Other debtors 11,374 -
Prepayments and accrued income 159,893 160,460
1,756,449 2,105,061

Trade debtors are stated after provisions for impairment of £nil (2024: £nil).

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
as restated
£    £   
Trade creditors 2,325,923 2,164,631
Corporation tax 152,161 247,776
Tax and social security 39,308 76,775
Other creditors 9,587 14,934
Foreign exchange forward
contracts 207,637 13,875
Accruals and deferred income 177,168 71,578
2,911,784 2,589,569

14. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2025 2024
as restated
£    £   
Within one year 836 836
Between one and five years 3,346 3,346
4,182 4,182

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

15. FINANCIAL INSTRUMENTS

2025 2024
£ £
Financial liabilities

Measured at fair value 207,637 13,875
207,637 13,875


Financial assets and liabilities which are measured at fair value through the profit and loss includes foreign exchange forward contracts.

16. PROVISIONS FOR LIABILITIES
2025 2024
as restated
£    £   
Deferred tax 34,038 12,456

Deferred
tax
£   
Balance at 1 April 2024 12,456
Accelerated capital allowances 21,582
Balance at 31 March 2025 34,038

17. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: as restated
£    £   
30 'A' Ordinary £1 30 -
(2024 - 0 )
60 'C' Ordinary £1 60 60
90 60

30 'A' Ordinary shares of £1 each were allotted as fully paid as a bonus issue out of reserves during the year.

The 'A' Ordinary shares have the right to receive dividends but do not have the right to vote unlike the 'C' Ordinary shares.

V.H. Bio Limited (Registered number: 02582192)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

18. RESERVES
Capital
Retained redemption
earnings reserve Totals
£    £    £   

At 1 April 2024 7,197,542 10,870 7,208,412
Profit for the year 1,293,265 1,293,265
Dividends (186,800 ) (186,800 )
Bonus share issue (30 ) - (30 )
At 31 March 2025 8,303,977 10,870 8,314,847

Called up share capital - represents the nominal value of shares that have been issued.

Retained earnings - includes all current and prior period retained profits and losses.

Capital redemption reserve - records the nominal value of shares repurchased by the company.

19. PENSION COMMITMENTS

The company operates a defined contributions pension scheme, the assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £168,336 (2024: £181,218). Contributions totalling £nil (2024: £nil) were payable to the fund at the balance sheet date.

20. RELATED PARTY DISCLOSURES

Other related parties
2025 2024
as restated
£    £   
Bonus issue of shares 30 -

21. ULTIMATE CONTROLLING PARTY

The controlling party is A J Wortley.